Azelaic Acid History & Development: How a Grain-Derived Acid Became a Women's Skin Essential

Where Azelaic Acid Comes From: The Grain-to-Clinic Origin Story

Azelaic acid did not begin in a pharmaceutical laboratory. It is a saturated nine-carbon dicarboxylic acid (nonanedioic acid, C9H16O4) that occurs naturally in wheat, rye, and barley and is produced as a metabolic byproduct when the skin-resident fungus Malassezia furfur oxidizes fatty acids on the skin surface. That biochemical accident turned out to be clinically significant.

Early Chemical Isolation

Chemists identified azelaic acid in the early twentieth century as a minor product of oleic-acid oxidation. It was catalogued as an industrial compound, used in polymer synthesis and lubricants, but generated no medical interest for decades. The compound sat in organic-chemistry reference texts, largely ignored by dermatologists.

The Pigmentation Connection That Changed Everything

The clinical pivot came in the 1970s when Italian dermatologist Maria Nazzaro-Porro observed that patients with tinea versicolor, a Malassezia-caused skin infection, showed localized areas of hypopigmentation. Her team hypothesized that a Malassezia metabolite was interfering with melanin synthesis. Working at the Istituto Dermopatico dell'Immacolata in Rome, Nazzaro-Porro and colleagues identified azelaic acid as the responsible compound and published foundational work through the late 1970s and early 1980s demonstrating that the acid inhibited tyrosinase, the rate-limiting enzyme in melanin production. That single finding opened three clinical directions simultaneously: hyperpigmentation, acne, and anti-infective therapy.

The Science of How Azelaic Acid Actually Works

Azelaic acid's appeal comes from the fact that it does not work through a single channel. It has at least three distinct mechanisms, each relevant to a different skin condition, and all three matter for women because the conditions they address (acne, rosacea, melasma) are disproportionately driven by hormonal fluctuation.

Tyrosinase Inhibition and Pigment Control

Tyrosinase converts tyrosine to DOPA and then to dopaquinone, the first committed step in melanin synthesis. Azelaic acid competitively inhibits tyrosinase with greater selectivity for hyperactive melanocytes than for normal ones, which is why it lightens post-inflammatory hyperpigmentation and melasma without causing the bleached, depigmented patches that hydroquinone can produce in darker skin tones. This selectivity matters enormously for women of color, who carry a higher burden of post-acne darkening and who have historically been excluded from trials for many topical agents.

Antimicrobial and Anti-Keratinization Effects

At 20 percent concentration, azelaic acid inhibits mitochondrial oxidoreductase enzymes in Cutibacterium acnes (formerly Propionibacterium acnes), disrupting the bacterium's ability to generate ATP. This is a mechanistically distinct antibacterial action compared with antibiotics, and critically, azelaic acid has shown no capacity to generate bacterial resistance in long-term use studies. The acid also normalizes follicular keratinization, reducing the comedone formation that underpins both non-inflammatory and inflammatory acne.

5-Alpha-Reductase Inhibition: The Hormonal-Acne Connection

This mechanism is the least discussed in consumer content and one of the most relevant to women. Azelaic acid inhibits type-I 5-alpha-reductase, the enzyme that converts testosterone to the more potent dihydrotestosterone (DHT) within the sebaceous gland. DHT is the primary androgen driver of sebum overproduction and enlarged pores.

For women with PCOS, whose androgen levels are already elevated at the level of ovarian production, topical 5-alpha-reductase inhibition at the skin level provides a local anti-androgenic effect that systemic treatments like spironolactone also target, but through a different route. This makes azelaic acid a rationally selected adjunct rather than just a "gentle alternative" to other actives. No published head-to-head trial in women with PCOS-driven acne has yet compared azelaic acid to topical spironolactone directly. That evidence gap is real, and the current recommendation to use it in PCOS-related acne is based on mechanism and extrapolated acne trial data rather than PCOS-specific RCTs.

Regulatory Development: From Italian Research to FDA Approval

The path from Nazzaro-Porro's bench work to approved product took roughly two decades of controlled clinical trials in Europe and North America.

European Formulation and Schering AG Development

Schering AG (Germany) licensed the compound in the early 1980s and developed the first 20 percent azelaic acid cream, marketed under the brand name Skinoren in Europe. European regulatory approval for acne came in the mid-1980s. The cream vehicle was selected partly for stability, because azelaic acid is poorly water-soluble and early aqueous formulations degraded quickly.

FDA Approval Timeline

The FDA approved 20 percent azelaic acid cream (Azelex) in 1996 for mild to moderate inflammatory acne vulgaris. A lighter 15 percent gel formulation (Finacea) received FDA approval in 2002 for rosacea, followed by a 15 percent foam formulation (Finacea Foam) approved in 2015. All three remain on the market; generic equivalents at both concentrations are now widely available.

The approval of a distinct rosacea formulation at a lower concentration reflects a deliberate regulatory and clinical distinction: the 15 percent gel achieves therapeutic anti-inflammatory effect in rosacea with a somewhat lower irritancy profile than the 20 percent cream, which is better suited to the comedonal and papular pathology of acne.

Comparator Evidence: Where Azelaic Acid Stands Against Established Actives

A key 2010 systematic review published in the Journal of Drugs in Dermatology and indexed at PMID 21034991 synthesized available randomized controlled trials and concluded that azelaic acid 20 percent showed comparable efficacy to benzoyl peroxide for inflammatory acne lesion counts. The same review noted comparable efficacy to tretinoin in some trial arms. That finding is clinically consequential because both benzoyl peroxide and tretinoin are contraindicated or used with caution in pregnancy, while azelaic acid carries a Pregnancy Category B designation.

Azelaic Acid Across the Female Life Span

Skin conditions do not occur in a hormonal vacuum. Azelaic acid's multi-mechanism profile makes it one of the few prescription topicals that is both effective and usable across nearly every female life stage.

Reproductive Years: Hormonal Acne and the Menstrual Cycle

Acne in adult women, defined as women older than 25, affects approximately 45 percent of women aged 21 to 30 and 26 percent of women aged 31 to 40, rates substantially higher than in adult men. The characteristic pattern is cyclical: lesions worsen in the week before menstruation when progesterone peaks and estrogen falls, driving sebum production. Azelaic acid's 5-alpha-reductase inhibition is active regardless of hormonal phase, meaning it provides a steady topical anti-androgenic effect that does not need to be timed around the cycle.

Trying to Conceive: A Critical Transition Point

Women stopping oral contraceptives to try to conceive often experience a rebound flare of hormonal acne within two to six months of pill cessation. At this specific moment, many first-line acne treatments become off-limits: retinoids are teratogenic, oral doxycycline should be avoided near conception, and isotretinoin carries a mandatory iPLEDGE pregnancy-prevention program. Azelaic acid fills this gap. Because it is rated Pregnancy Category B, it can be continued throughout the conception window without requiring a washout period.

Pregnancy: The Melasma and Acne Overlap

Pregnancy-related skin changes are common. Melasma ("the mask of pregnancy") develops in up to 70 percent of pregnant women, driven by estrogen and progesterone-stimulated upregulation of melanocyte-stimulating hormone. Acne also frequently worsens in the first and second trimesters due to rising human chorionic gonadotropin and progesterone.

Azelaic acid addresses both simultaneously. The tyrosinase-inhibiting mechanism directly targets melasma, and the antimicrobial and anti-keratinization effects address concurrent acne. No other single prescription topical covers both indications safely in pregnancy. The ACOG guidance on skin conditions in pregnancy does not list azelaic acid as contraindicated and supports use of well-tolerated topicals at standard doses.

Postpartum and Lactation

Azelaic acid is excreted into breast milk. Endogenous azelaic acid is naturally present in human milk at detectable concentrations, meaning the topical dose adds a small increment above baseline rather than introducing a foreign compound. The National Institutes of Health LactMed database classifies topical azelaic acid as compatible with breastfeeding when applied away from the breast and nipple area, with oral infant exposure estimated to be negligible given the low systemic absorption of topical application (approximately 4 percent of applied dose reaches systemic circulation). The postpartum period also commonly brings both acne flares driven by rapid estrogen withdrawal and persistent post-inflammatory hyperpigmentation from pregnancy-related melasma, making continued use clinically rational.

PCOS: The Androgen-Skin Interface

Women with polycystic ovary syndrome carry a substantially elevated androgen burden that produces a distinct acne phenotype: deep, cystic, and concentrated along the jawline and neck. Standard topical treatments often produce partial responses in PCOS-related acne because topical agents alone cannot fully counter systemic androgen excess. Systemic options such as spironolactone or combined oral contraceptives address the hormonal root cause. Azelaic acid's topical 5-alpha-reductase inhibition adds a local anti-DHT layer that may complement systemic treatment.

If pregnancy is desired, COCs cannot be used and spironolactone is contraindicated in pregnancy. Azelaic acid is one of the few agents usable without interruption from PCOS management through the conception window and into pregnancy itself.

Perimenopause: Rosacea Flares and Shifting Skin

During perimenopause, declining estrogen alters skin barrier function, reduces collagen density, and may worsen rosacea. Vasomotor symptoms including hot flashes can trigger rosacea flushing episodes. The Menopause Society (formerly NAMS) notes that skin sensitivity and flushing-associated conditions frequently worsen during perimenopause, and women are diagnosed with rosacea at higher rates than men across their lifetime.

The 15 percent azelaic acid gel formulation is particularly suited to perimenopausal skin because it is free of retinoids, glycolic acid, and alcohol-based vehicles that can irritate a compromised barrier. Its anti-inflammatory mechanism, which includes reduction of reactive oxygen species in affected skin, works independently of hormonal status and does not interact with hormone therapy if the patient is using systemic or topical estrogen.

Post-Menopause: Continued Role in Skin Tone

In post-menopausal women, sustained hyperpigmentation from decades of UV exposure and prior melasma can coexist with the skin-barrier changes of estrogen deficiency. Azelaic acid at 20 percent remains appropriate for post-inflammatory hyperpigmentation maintenance without the cutaneous atrophy risk associated with long-term topical corticosteroids or the photosensitivity of alpha-hydroxy acids.

Pregnancy and Lactation Safety: The Full Picture

Pregnancy Category B means animal reproduction studies have not demonstrated fetal risk and there are no adequate, well-controlled studies in pregnant women. This is not the same as proven safety in humans, and women should not interpret Category B as equivalent to Category A (studied and found safe in controlled human trials). No drug earns Category A in dermatology because no one runs placebo-controlled teratogen trials in pregnant women.

What the data show:

• Animal teratogenicity studies at doses well above human dermatological use found no fetal harm.
• Systemic absorption from topical application is low: approximately 3 to 4 percent of the applied dose is absorbed percutaneously, with peak plasma concentrations far below endogenous azelaic acid levels.
• Human azelaic acid plasma concentrations at baseline (before any topical application) range from 19 to 63 ng/mL. Twice-daily topical application raises this by a small, transient margin.
• No published case series or pharmacovigilance database reports a pattern of fetal abnormality associated with gestational azelaic acid use.

Contraception requirement: Azelaic acid itself is not a teratogen and carries no mandatory contraception requirement comparable to isotretinoin or valproate. However, it is often prescribed alongside agents that do require contraception (for example, topical tretinoin in non-pregnant women with acne). Clinicians should clarify contraception requirements for the full regimen, not just the azelaic acid component.

Avoid contact with: eyes, mucous membranes, and open skin wounds. No specific area-avoidance is required during pregnancy beyond standard cosmetic-avoidance of broken skin, but during breastfeeding the drug should not be applied to the breast or nipple.

Formulation Science: Why Concentration and Vehicle Matter

The difference between 15 percent and 20 percent is not merely incremental. The two concentrations were developed for different targets, optimized in different vehicles, and have distinct regulatory indications.

| Formulation | Concentration | Indication | Vehicle | Approval Year | |---|---|---|---|---| | Azelex cream | 20% | Acne vulgaris | Oil-in-water cream | 1996 | | Finacea gel | 15% | Rosacea | Aqueous gel with glycerol | 2002 | | Finacea Foam | 15% | Rosacea | Foam with dimethicone | 2015 | | Generics (multiple) | 15-20% | Acne / rosacea | Varies | 2000s-present |

The foam vehicle, introduced in 2015, was designed to reduce the white residue left by the gel and improve adherence. Women cited cosmetic elegance as a primary reason for discontinuing the gel in early observational surveys. Adherence matters because azelaic acid requires consistent twice-daily application for at least four to eight weeks before meaningful improvement is visible.

Generic formulations are bioequivalent by FDA standards but may use different preservative systems or emollients. A small number of women report differences in skin feel between branded and generic versions, though no comparative efficacy trial has demonstrated a clinical outcome difference.

The Evidence Gap: What We Do Not Yet Know About Azelaic Acid in Women

Honesty about evidence limits is as important as the evidence itself. Here is what remains unsettled:

• PCOS-specific RCTs are absent. Every recommendation to use azelaic acid in PCOS-driven acne is extrapolated from general acne trials, not from trials enrolling women with confirmed PCOS and documented androgen excess.
• Melasma in pregnancy lacks an RCT. The use of azelaic acid for gestational melasma rests on mechanism, safety profile, and expert opinion rather than a prospective randomized trial in pregnant participants.
• Perimenopausal rosacea data is thin. Rosacea trials have historically enrolled mixed populations without stratifying by menopausal status. Whether azelaic acid's efficacy in rosacea differs in estrogen-deficient skin has not been formally tested.
• Long-term pigment outcomes in darker skin tones (Fitzpatrick IV-VI) are under-studied. Women of color are the population most affected by post-inflammatory hyperpigmentation and melasma, yet they remain underrepresented in published azelaic acid trials.

These gaps do not negate the compound's value. They are reasons for ongoing research and for clinicians to individualize rather than generalize.

Who This Is Right For and Who Should Pause

Well-Suited for Azelaic Acid

• Women with hormonal acne who are pregnant, breastfeeding, or trying to conceive.
• Women with PCOS-related acne who cannot or prefer not to use systemic options.
• Women with rosacea during perimenopause, particularly those also using hormone therapy where drug interactions must be minimized.
• Women with post-inflammatory hyperpigmentation or melasma across Fitzpatrick skin types I-VI, given the selective melanocyte targeting.
• Women who cannot tolerate retinoids, benzoyl peroxide, or antibiotic-based regimens due to sensitivity or resistance concerns.

Reasons to Reconsider or Monitor Closely

• Known hypersensitivity to propylene glycol (present in some formulations) or azelaic acid itself. Allergic contact dermatitis is uncommon but reported.
• Asthma: a small number of cases of worsening asthma have been reported with topical azelaic acid. The causal link is not established, but women with reactive airway disease should monitor symptoms.
• Very fair skin (Fitzpatrick I-II) using the 20 percent concentration: hypopigmentation at application sites is a rare but documented adverse effect. This is more commonly seen with prolonged use in patients with fair baseline pigmentation.